Research programme: transdermal therapeutics - CAGE Bio/Nitto Denko
Latest Information Update: 28 Aug 2024
At a glance
- Originator CAGE Bio; Nitto Denko
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for research development in Unspecified in Japan (Transdermal)
- 07 Jul 2020 CAGE Bio and Nitto Denko agree to co-develop transdermal therapeutics in Japan for undisclosed indication
- 07 Jul 2020 CAGE Bio in-licenses deep eutectic ionic liquid technology from University of California